The Renoir study will help us learn if an investigational vaccine is safe and can help the body produce antibodies and cells to fight off RSV infection and disease in older adults. Respiratory syncytial virus (RSV) is a common and pervasive cause of acute respiratory illness with no effective treatment or prevention options. However, sometimes RSV can be more serious, especially in babies, older a
dults, and those with heart or lung problems or weakened immune systems. Severe RSV can cause problems like pneumonia (an infection of the lungs). It can also worsen symptoms for people who have chronic obstructive pulmonary disease (COPD) or congestive heart failure (CHF). Around the world, there is an urgent need for a vaccine that can prevent RSV in older adults. Like the flu season, RSV season usually happens between late fall and early spring, lasting approximately six to nine months depending on the region or country. This study will be conducted over the course of three RSV seasons. There is usually one RSV season per year, so participants could be in this study for about three years.
